Table of contents


Please note that this product was withdrawn from the Community register of designated orphan medicinal products in November 2012 at the end of the period of market exclusivity.

On 18 October 2000, orphan designation (EU/3/00/006) was granted by the European Commission to Oxford GlycoSciences (UK) Ltd, United Kingdom, for 1,5-(butylimino)-1,5-dideoxy, D-glucitol for the treatment of Gaucher disease.

1,5-(butylimino)-1,5-dideoxy, D-glucitol for the treatment of Gaucher disease has been authorised in the EU as Zavesca since 20 November 2002.

The sponsorship was transferred to Actelion Registration Limited, United Kingdom, in March 2003.

Key facts

Active substance
1,5-(Butylimino)-1,5-dideoxy, D-glucitol
Disease / condition
Treatment of Gaucher disease
Date of first decision
EU designation number

Sponsor's contact details

Actelion Registration Limited
BSI Building 13th floor
389 Chiswick High Road
W4 4AL
United Kingdom
Tel. + 44 (0)20 8987 3320
Fax + 44 (0)20 8987 3322

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating